MedPath

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Phase 2
Completed
Conditions
Non-small-cell Lung Cancer
Interventions
Registration Number
NCT01138163
Lead Sponsor
Peregrine Pharmaceuticals
Brief Summary

The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
121
Inclusion Criteria
  • Adults over age 18 years of age with a life expectancy of at least 3 months.
  • Histologically or cytologically confirmed stage IIIB or stage IV non squamous non-small-cell lung cancer (NSCLC) who have progressed after 1 chemotherapy regimen.
  • Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST, Version 1.1) on cross-sectional imaging that is at least 2 cm in longest diameter.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • Adequate hematologic, renal, and hepatic function.
  • PT/INR ≤ 1.5 × ULN; aPTT time ≤ 1.5 × ULN.
  • New York Heart Association classification I or II
Exclusion Criteria
  • Squamous, small cell, or mixed histology.
  • Known history of bleeding diathesis or coagulopathy.
  • Cavitary tumors or tumors invading or abutting large blood vessels.
  • Bleeding: Clinically significant bleeding such as gross hematuria, GI bleeding and hemoptysis within 12 months of Screening.
  • Venous thromboembolic events within 6 months of screening.
  • Ongoing therapy with oral or parenteral anticoagulants.
  • Concurrent estrogens, anti-estrogens or progesterone compounds.
  • Radiotherapy within 2 weeks or major surgery within 4 weeks preceding Study Day 1.
  • Symptomatic or clinically active brain metastases.
  • Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris within 6 months of screening.
  • Grade 2 or higher peripheral neuropathy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Docetaxel plus bavituximab 1 mg/kgDocetaxel plus bavituximab or placebo-
Docetaxel plus bavituximab 3 mg/kgDocetaxel plus bavituximab or placebo-
Docetaxel plus placeboDocetaxel plus bavituximab or placebo-
Primary Outcome Measures
NameTimeMethod
Objective Response RateUntil disease progression
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (53)

The Center for Hematology-Oncology/Boca Raton Community Hospital, Inc

🇺🇸

Boca Raton, Florida, United States

Cedar Valley Medical Specialists, PC

🇺🇸

Waterloo, Iowa, United States

Jewish Hospital

🇺🇸

Louisville, Kentucky, United States

Northwest Georgia Oncology Centers, PC

🇺🇸

Marietta, Georgia, United States

Hanover Medical Specialists, PA

🇺🇸

Wilmington, North Carolina, United States

American Institute of Research

🇺🇸

Whittier, California, United States

Frederick Memorial Hospital Regional Cancer Therapy Center

🇺🇸

Frederick, Maryland, United States

Florida Cancer Specialists

🇺🇸

Fort Myers, Florida, United States

Medulla Chemotherapy and Immunotherapy Clinic

🇬🇪

Tbilisi, Georgia

Dayton Clinical Oncology Program

🇺🇸

Dayton, Ohio, United States

Pennsylvania State Hershey Cancer Institute

🇺🇸

Hershey, Pennsylvania, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

JSC A.Gvamichava National Oncology Center

🇬🇪

Tbilisi, Georgia

Mary Crowley Cancer Research Centers

🇺🇸

Dallas, Texas, United States

Georgia Cancer Specialists, PC

🇺🇸

Atlanta, Georgia, United States

Coastal Bend Cancer Center

🇺🇸

Corpus Christi, Texas, United States

SMS Medical College Hospital

🇮🇳

Jaipur, Rajasthan, India

Medical Oncology Care Associates

🇺🇸

Orange, California, United States

South Bay Hematology Oncology

🇺🇸

Campbell, California, United States

Nebraska Hematology Oncology, PC

🇺🇸

Lincoln, Nebraska, United States

O.P. Jindal Institute of Cancer & Research

🇮🇳

Hisar, Haryana, India

Kidwai Memorial Institute of Oncology

🇮🇳

Bangalore, Karnataka, India

All India Institute of Medical Sciences

🇮🇳

Delhi, India

Ironwood Cancer and Research Center

🇺🇸

Chandler, Arizona, United States

Mahavir Cancer Sansthan

🇮🇳

Patna, Bihar, India

Bharath Hospital and Institute of Oncology

🇮🇳

Mysore, Karnataka, India

Kodlikeri Memorial Hospital

🇮🇳

Aurangabad, Maharashtra, India

Nizam's Institute of Medical Sciences

🇮🇳

Hyderabad, Andra Pradesh, India

Bangalore Institute of Oncology Specialty Centre

🇮🇳

Bangalore, Karnataka, India

City multi-field clinical hospital # 4, Department of chemotherapy; Dnipropetrovsk State Medical Academy, Chair of Oncology and Medical Radiology;

🇺🇦

Dnipropetrovsk, Ukraine

Uzhgorod Central City Clinical Hospital, City Oncology Center

🇺🇦

Uzhgorod, Ukraine

Shatabdi Superspecialty Hospital

🇮🇳

Nashik, Maharashtra, India

State Institution of Healthcare "Pyatigorsk Oncology Dispensary"

🇷🇺

Stavropol', Russian Federation

State Institution of Healthcare of Yaroslavl Region "Regional Clinical Oncology Hospital"

🇷🇺

Yaroslavl, Russian Federation

Chhatrapati Shahuji Maharaj Medical University

🇮🇳

Lucknow, Uttar Pradesh, India

Institution of Russian Academy of Medical Science "Russian Oncology Scientific Centre named after N. N. Blokhina RAMN"

🇷🇺

Moscow, Russian Federation

BiBi General Hospital & Cancer Centre

🇮🇳

Hyderabad, Andhra Pradesh, India

Shanti Mukund Hospital Curie Cancer Center

🇮🇳

Delhi, India

South Carolina Oncology Associates

🇺🇸

Columbia, South Carolina, United States

Cancer Care Clinic

🇮🇳

Nagpur, Maharashtra, India

State Institution of Healthcare " Ivanovo Regional Oncology Dispensary "

🇷🇺

Ivanovo, Russian Federation

Kyiv City Oncology Hospital, Thoracal Department

🇺🇦

Kyiv, Ukraine

State Medical Preventive Institution "Chelyabinsk Regional Clinical Oncology"

🇷🇺

Chelyabinsk, Russian Federation

State Educational Institution of Higher Professional Education "Saint-Petersburg State Medical University named after academician I.P. Pavlov of Federal Agency of Healthcare and Social Development"

🇷🇺

Saint Petersburg, Russian Federation

State Institution of Healthcare "Tula Regional Oncology Dispensary"

🇷🇺

Tula, Russian Federation

Municipal Clinical Medical and Prophylactic Institution "Donetsk Regional Antineoplastic Center", onco-chemotherapy

🇺🇦

Donetsk, Ukraine

State Institution "Institute of Medical Radiology named after S.P. Grygoryev of AMS of Ukraine", department of chemotherapy

🇺🇦

Kharkiv, Ukraine

The Christ Hospital Cancer Center Research

🇺🇸

Cincinnati, Ohio, United States

Oncology/ Hematology Care, Inc

🇺🇸

Cincinnati, Ohio, United States

Sarah Cannon Research Institute, LLC

🇺🇸

Nashville, Tennessee, United States

University of Utah Hospitals and Clinics, Huntsman Cancer Institute

🇺🇸

Salt Lake City, Utah, United States

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Ruby Hall Clinic

🇮🇳

Pune, Maharashtra, India

© Copyright 2025. All Rights Reserved by MedPath